Edition:
United Kingdom

Formycon AG (FYB.DE)

FYB.DE on Xetra

31.30EUR
16 Feb 2018
Change (% chg)

€0.35 (+1.13%)
Prev Close
€30.95
Open
€31.10
Day's High
€31.95
Day's Low
€30.95
Volume
5,860
Avg. Vol
6,642
52-wk High
€39.38
52-wk Low
€21.56

Latest Key Developments (Source: Significant Developments)

Formycon And Aristo Pharma Are Founding Joint Venture For Development Of FYB202
Friday, 22 Dec 2017 

Dec 22 (Reuters) - FORMYCON AG ::PTA-ADHOC: FORMYCON AG: FORMYCON AND ARISTO PHARMA ARE FOUNDING A JOINT VENTURE FOR THE DEVELOPMENT OF FYB202.IS INVOLVED WITH 24.9 PERCENT OF DEVELOPMENT COSTS AND POTENTIAL LICENSING REVENUES FROM MARKETING OF FYB202.  Full Article

Formycon 9-month Net Loss at 5.11 Million Euros
Monday, 27 Nov 2017 

Nov 27 (Reuters) - FORMYCON AG ::REPORTS OPERATING AND FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2017.‍EURO 25 MILLION SALES TARGET FOR WHOLE OF 2017 CONFIRMED​.‍IN FIRST THREE QUARTERS, FORMYCON AG AS ACTUAL OPERATIONAL UNIT ACHIEVED A TURNOVER OF EURO 7.41 MILLION​.‍FORMYCON AG 9-MONTH EBITDA EUR -4.48 MILLION, OPERATING RESULT AT EUR -5.07 MILLION, AND NET EARNINGS AT EUR -5.11 MILLION​.  Full Article

Formycon confirms management board members until mid-2022
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - FORMYCON AG ::DGAP-NEWS: FORMYCON AG: FORMYCON SETS COURSE FOR THE FUTURE AND CONFIRMS MANAGEMENT BOARD MEMBERS UNTIL MID-2022.‍CONTRACTS OF CEO CARSTEN BROCKMEYER AND CFO NICOLAS COMBÉ EXTENDED UNTIL JUNE 30, 2022​.‍APPOINTMENT OF COO STEFAN GLOMBITZA REMAINS UNCHANGED​.  Full Article

Formycon H1 turnover down at 8.76 mln euros
Tuesday, 20 Sep 2016 

Formycon AG : H1 turnover was 8.76 million euros ($9.79 million), compared to 9.82 million euros in same period previous year . Annual result is greatly dependent on whether FYB202 project will be partnered in 2016 . H1 operating result stood at -1.17 million euros compared to 1.5 million euros during same period last year .Company continues to anticipate a rise in turnover to over 20 million euros for current year.  Full Article

Formycon Q1 sales revenues and other earnings at 6.34 mln euros
Thursday, 19 May 2016 

Formycon AG : From January to March, EBITDA was -0.02 million euros (-0.3 million euros) based on a quarterly result of -0.19 million euros (-0.57 million euros) . Q1 at group level, sales revenues and other earnings totaled 6.34 million euros ($7.11 million), which represents an increase of 3.34 million euros . As already communicated, we anticipate a growth in sales to over 20 million euros for whole year at group level .Annual result will depend greatly on time at which we partner our fyb202 project.  Full Article

Momenta, Mylan plan trial of biosimilar to Regeneron eye drug

Jan 3 Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.